OBJECTIVES: Microvascular invasion and microlymphatic permeation are indicators of microscopic tumour invasion into small vessels and have been considered to be powerful prognostic indicators for non-small-cell lung cancer (NSCLC). Several studies have suggested that these should be included in the TNM classification, but, there have been conflicting results regarding the prognostic impact of microvascular invasion and microlymphatic permeation. The aim of the current study was to clarify the prognostic impact of microvascular invasion and microlymphatic permeation on resected node-negative NSCLC by comparative analyses.
INTRODUCTION
Lung cancer is the leading cause of cancer-related death worldwide. The best treatment for early-stage non-small-cell lung cancer (NSCLC) is surgical resection. Within stage I disease, however, some patient characteristics are associated with worse survival, and many researchers have tried to identify the relevant prognostic factors. Microvascular invasion (MVI) and microlymphatic permeation (MLP) have been reported to be powerful prognostic indicators for resected NSCLC [1] [2] [3] [4] [5] [6] [7] [8] , and some investigators have suggested that these factors should be reflected in the TNM staging system. The most recent (7th) edition of the TNM classification of lung cancer dose not include MVI or MLP in the staging system, but has described both factors as 'optional descriptors' which deserved further investigation [9] . However, there have been conflicting reports regarding both. Some investigators have reported that only MLP, but not MVI, was significantly related to worse survival [6, 10, 11] , whereas others stated opposite results [2, 5] . Some authors considered both blood vessel invasion (true MVI) and lymphatic permeation (MLP) to be MVI [4, 12] , whereas others differentiate between blood vessels and lymphatic channels. Therefore, it remains unknown which, of MVI and MLP, has more impact on survival, and whether these factors should be separately examined. In this study, we attempted to clarify the clinicopathological features and prognostic impact on survival of MVI-and MLP-positive tumours in completely resected node-negative NSCLC by comparative analyses.
PATIENTS AND METHODS

Patient selection
A total of 2132 consecutive patients with NSCLC underwent pulmonary resection at our institution between 1993 and 2005. Among them, a total of 1039 patients with pathological T1a-3N0M0 who underwent complete resection of greater than lobectomy were included in this retrospective study. This study was approved by the institutional review board of our institution in 2010, and the need to obtain written informed consent was waived. Patients with the following characteristics were excluded: incomplete resection; neoadjuvant therapy; limited resections; T4, N1-3 and M1 disease and non-T-size-based T2a/T3 disease such as visceral pleural invasion (VPI) and chest wall invasion.
Histopathological examination
The surgical specimens were fixed in 10% formalin and underwent routine histopathological workup with paraffin embedding.
Sections (4-µm thick) were cut and stained with haematoxylin and eosin (H&E). Victoria blue-van Gieson (VVG) staining to visualize elastic fibres was also routinely performed in all sections containing tumour cells to evaluate MVI and pleural invasion. MVI was determined to be positive if conspicuous clusters of tumour cells were present inside the microscopic lumen with a VVG-stained elastic layer in any section ( Fig. 1A and B) . MLP was considered to be positive when tumour cells were floating in VVG-negative, thin endothelial-lined channels with no supporting smooth muscles or elastic fibres in any section ( Fig. 1C and D) . As the artifactual spaces around the cancer nests were often indistinguishable from lymphatic vessels containing tumour emboli, when floating tumour cells were identified in lumens within the bronchovascular bundle, subpleural or interlobular pleural spaces, lymphatic permeation was concluded to be present. When we were not confident that the findings represented lymphatic permeation, we did not record the case as positive. Pathological evaluation using H&E and VVG staining was performed by two or more pathologists who were blinded to the clinical outcome, and the results were retrospectively collected.
Patient follow-up
We examined the patients at 3-month intervals for the first 2 years and at 6-month intervals thereafter on an outpatient basis. The follow-up evaluation included physical examination, chest radiography and blood examination including pertinent tumour markers. Whenever any symptoms or signs of recurrence were detected, further evaluations including computed tomography (CT) scans of the chest and abdomen, brain magnetic resonance imaging and bone scintigraphy were performed. Since 2004, integrated positron emission tomography and CT (PET-CT) was also performed for selected patients.
Statistical analysis
Two-category comparison was performed by the Pearson's χ 2 test. Overall survival (OS) was measured from the date of surgery to the date of death from any cause or last follow-up. The median follow-up period was 108 months (range 1-208). All cumulative survival rates were estimated using the Kaplan-Meier method, and differences in variables were evaluated using the log-rank test. Cox proportional hazards multivariate models were used to identify the independent prognostic factors. A P-value ≤0.05 was considered to represent statistically significant differences. The analyses were performed using statistical software JMP 8.0 (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism 5.02 (GraphPad Software, San Diego, CA, USA).
RESULTS
The patient characteristics are shown in Table 1 . The median age was 66 years (range 20-89). There were 601 (57.8%) men and 438 (42.2%) women. Adenocarcinoma was the most common histology (71.9%). The distribution of p-T factors (tumour size) was as follows: T1a (≤2 cm), 354 (34.1%); T1b (2-3 cm), 277 (26.7%); T2a (3-5 cm), 315 (30.3%); T2b (5-7 cm), 62 (5.9%); T3 (>7 cm), 31 (3.0%). Overall, MVI and MLP were observed in 358 (34.5%) and 205 (19.7%) patients, respectively. MVI alone (MVI +/MLP−), MLP alone (MVI−/MLP+) and both MVI and MLP (MVI +/MLP+) were observed in 231 (22.2%), 78 (7.5%) and 127 (12.2%) patients, respectively. The prevalence of MVI was significantly higher in patients >70 years (P < 0.001), male patients (P < 0.001), patients with non-adenocarcinomas (P < 0.001) and patients with large-sized tumours (P < 0.001). The prevalence of MLP showed a similar trend. MLP was significantly prevalent in male patients (P = 0.05), patients with non-adenocarcinoma (P = 0.006) and large-sized tumours (P < 0.001) ( Table 2 ). During the follow-up, 191 (18.4%) had recurrence ( Table 3 pathological factors revealed that tumour size, histology and pleural invasion, in addition to MVI+, MLP+ and MVI+/MLP+, were significant prognostic factors. The 5-year OS rate was significantly lower in patients with MVI-positive (65.3%) compared with MVI-negative tumours (89.8%, P < 0.001), patients with MLP-positive (68.3%) relative to MLP-negative tumour (84.6%, P < 0.001), patients with MVI+/MLP+ (58.3%) compared with other population (MVI−/MLP−, MVI+/MLP− and MVI−/MLP+) (84.6%, P < 0.001), patients with large-sized tumour (>3 cm, 67.4%) compared with small-sized tumour (≤3 cm, 90.5%, P < 0.001), patients with non-adenocarcinoma (65.2%) compared with adenocarcinoma (87.7%, P < 0.001) and patients with tumours having pleural invasion (55.6%) compared with tumours without pleural invasion (85.5%, P < 0.001). Multivariate analysis demonstrated that a tumour size of >3 cm (HR 1.976, P < 0.001), non-adenocarcinoma histology (HR 1.757, P < 0.001), pleural invasion (HR 1.438, P = 0.001) and MVI+ (HR 1.648, P < 0.001) were independent poor prognostic factors associated with survival (Table 4) . Neither MLP+ nor MVI+/MLP+ were statistically significant poor prognostic factors (HR 1.138, P = 0.588; HR 1.149, P = 0.618). We analysed the OS of groups of T1a-b and T2a-b patients stratified by different T-size categories ( Fig. 3A and B) . To evaluate the individual prognostic impact of both MVI and MLP, the patients with tumours which were double positive for both MVI and MLP (n = 127) were excluded from this analysis. In the T1a-b category, the presence of either MVI or MLP had a statistically significant negative prognostic impact on survival. (Fig. 3A) . On the other hand, in the T2a-b category, only MVI-positive T2a-b showed significantly lower OS rates than the dnT2a-b group, similar to the dnT3 group (5-year OS: dn T2a-b, 83.5%; MVI-positive T2a-b, 60.6%, P < 0.001; dnT3, 53.8%; P = 0.316). The MLP-positive T2a-b group showed statistically similar survival (5-year OS, 86.2%) to the dnT2a-b group (P = 0.856) (Fig. 3B ).
DISCUSSION
The importance of MVI and MLP as prognostic factors for resected NSCLC has been repeatedly reported by many investigators, including in our previous report [1-8, 10, 12] . Although, both MVI and MLP are indicators of microscopic tumour invasion into small vessels and are considered to be stages leading to tumour metastasis, it remains unknown which factor has more impact on survival because many studies have focussed only on either MVI or MLP. In this study, we performed a comparative survival analysis of patients with both MVI and MLP. The results indicated that the MVI-positive population had worse OS than the MLP-positive population, and multivariate analysis revealed that MVI, but not MLP, was an independent prognostic factor. When the presence or absence of MVI and MLP was incorporated in the TNM staging system, patients with MVI had significantly lower OS rate than the corresponding MVI-negative population in the T1a through T2b groups. The OS of patients in the T1a-b/MVI+ and T2a-b/MVI+ was statistically worse than that of patients in the dnT1a-b and dnT2a-b groups, and similar to that of patients in the dnT2a and dnT3 groups, respectively. On the other hand, the OS of the T1a-b/MLP+ group was worse than that of the dnT1a-b group and similar to that of the dnT2a group, but, the OS of the T2a-b/MLP+ group did not differ from that of the dnT2a-b group. Several studies have reported that MVI, but not MLP, is a poor prognostic factor of survival in patients with p-stage I NSCLC. Macchiarini et al. [13] reported that MVI was a predictor of postoperative recurrence and a poor prognostic factor in p-stage IA NSCLC patients. More recently, Shoji et al. [2] examined 217 p-stage IA NSCLC patients and demonstrated that MVI, but not MLP, was an independent prognostic factor. The results of the current study, which included a large number of patients with not only stage I but also higher stages, were similar to those of these previous studies, and indicate that the presence of MVI has a stronger prognostic impact on survival than MLP in patients with nodenegative NSCLC. This further indicates that tumour cells from node-negative NSCLC may metastasize preferentially via the blood vessels rather than the lymphatic channels, and thus MVI can be considered stronger prognostic factor. Several investigators have considered MVI to be a combination of blood vessel invasion and MLP [3, 12] . However, as each has a different prognostic impact on survival, MVI and MLP should be examined separately. The method of differentiating between MVI and MLP is important. We usually use H&E and VVG stains on all tumours. Elastic stains including VVG staining provide the reliable detection and differentiation of MVI and MLP. MVI can be clearly differentiated from MLP by elastic stains because only the vascular walls contain elastic fibres. The reported detection rates of MVI and MLP in pathological stage I tumours without any elastic stains were 11-16 and 0-3%, respectively [14, 15] . In contrast, detection rates for MVI and MLP with elastic stains were 27-56 and 40-52%, respectively [10, 13, 16] . Generally, the reported detection rates of MVI and MLP have been higher in studies which used elastic stains to evaluate MVI. Elastic staining enables pathologists to identify MVI more precisely and to distinguish MVI from MLP. In the latest (7th) edition of the TNM classification, VPI is clearly defined, and elastic staining has been considered the optimal method of evaluating VPI [17] . Therefore, the routine use of elastic staining in the pathological examination of lung cancer is recommended, not only for VPI determination but also for identifying and differentiating MVI and MLP. However, in identifying MLP, the artificial spaces around the cancer nests are sometimes indistinguishable from MLP [18] . Recently, antibodies against D2-40 and podoplanin have been reported to be useful for identifying lymphatic vessels in various human cancers including NSCLC [19, 20] . Both antipodoplanin and D2-40 antibodies have a sensitivity and specificity for lymphatic endothelium of >95% [19] . Further studies are required to establish standardized criteria for the diagnosis of MLP. The current data demonstrated that the MVI-positive population had significantly worse OS from the T1a group through the T2b group. Moreover, recent meta-analysis has shown survival benefit from cisplatin-based adjuvant chemotherapy in patients with stage II or higher NSCLC (LACE). A large adjuvant chemotherapy trial and meta-analysis conducted in Japan revealed that adjuvant chemotherapy with oral uracil-tegaful (UFT) had a survival benefit for stage IB adenocarcinoma patients, and demonstrated a tendency to improve survival even in patients with T1bN0M0. From the results of these studies, T1b-2aN0M0 and T2bN0M0 tumours may be candidates for adjuvant oral UFT and adjuvant cisplatin-based chemotherapy, respectively. In the current study, not only T1b/MVI+ but also T1a/MVI+ subgroups showed a significantly worse prognosis, consistent with the dnT2a subgroup. The T2a-b/MVI+ subgroup also showed significantly worse survival, similar to the dnT3 subgroup. Therefore, we suggest that T1a-b/MVI+ and T2a-b/MVI+ should be upstaged to T2a and T3, respectively. Patients with T1aN0M0/ MVI+ and T2aN0M0/MVI+ may be good candidates for adjuvant oral UFT and adjuvant cisplatin-based chemotherapy, respectively. However, a limitation of the present study is that our proposal is incomplete, and must be verified by internationally collected multi-institutional data. Moreover, we recently reported the importance of MVI location (i.e. intratumoural or extratumoural) [21] . Among 1000 consecutive patients with NSCLC, intratumoural MVI (v1) and extratumoural MVI (v2) were identified in 428 (42.8%) and 32 (3.2%) patients, respectively. Although the v2 group was small, but showed significantly worse OS than the v1 group (5-year OS: v1, 55.9%; v2, 44.0%; P = 0.010). The location data of MVI should be also collected internationally for future validation.
In conclusion, the results of this study indicate that MVI and MLP have differing impacts on survival, and that MVI, rather than MLP, is a potent prognostic factor in resected nodenegative NSCLC. MVI and MLP should be examined separately by elastic stains, and further data should be collected internationally, for consideration for the next revision of the TNM staging system.
APPENDIX. CONFERENCE DISCUSSION
Dr F. Detterbeck (New Haven, CT, USA): I have just a general comment. I think that we have to be careful with defining additional prognostic factors. It is always easy to take a set of patients and find something of statistical significance. It is often harder to repeat that in other studies. We certainly have many examples of prognostic factors that then are controversial in various studies and many fewer factors that end up being really valid. I think it is important work, but we have to look at it in a broader context.
One of my questions is, do you think that you have a better way of defining this that may be the key to resolving some of the controversies? My impression has been that the way that microvascular lymphatic invasion has been defined in other studies has been somewhat variable and not as consistent and that that is part of the reason why we haven't really been able to sort that out as well as we would like. Do you think this is potentially a better way, using elastic stains and as you have defined it?
Dr Hishida: This is a difficult question. There are many controversies about the different definitions of microvascular invasion and microlymphatic permeation. There are many controversies regarding the definition. So to resolve these issues, we need a consensus on what is the exact definition of the correct positive indicator. So for us, probably we need a consensus meeting to define exactly the definition.
Dr Detterbeck: Agree, and that would be somewhat of a comment of mine as well. There are many studies where people recommend that their finding should be part of the new staging system when it is revised again in 2017, but I think we have to be a little bit careful about that, because, remember, the stage classification, the accepted things were done because they were consistent in various studies and various regions and various histologic types and so forth, and I think we have to be more careful about recommending that. Maybe a good recommendation would be that this be considered in arriving at a consensus of how to define this. It might be a better first start.
Dr G. Veronesi (Milan, Italy): Do you think that the different prognostic impact of the two variables adenocarcinoma and non-adenocarcinoma tumours may be related to a stage bias or were they independent factors not related to the stage? I mean, maybe adenocarcinoma were diagnosed at an earlier stage.
Dr Hishida: Probably, I think so, yes. But other studies revealed a different result. Adenocarcinoma had more chance of having microvascular invasion than microlymphatic permeation. But in my study, non-adenocarcinoma had a higher percentage of a positive rate of microvascular invasion than microlymphatic permeation. The reason is that adenocarcinoma treated in Japan, including many early stages, was comprised of BAC, bronchoalveolar carcinoma, and showing ground-glass opacity on CT scan. That's why, I think.
